Cargando…

Moderate Renal Impairment Does Not Impact the Ability of CSL112 (Apolipoprotein A‐I [Human]) to Enhance Cholesterol Efflux Capacity

CSL112 (apolipoprotein A‐I [human]) is a novel intravenous formulation of plasma‐derived apolipoprotein A‐I (apoA‐I) that enhances cholesterol efflux capacity. Renal impairment is a common comorbidity in acute myocardial infarction patients and is associated with impaired lipid metabolism. The aim o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gille, Andreas, Duffy, Danielle, Tortorici, Michael A., Wright, Samuel D., Deckelbaum, Lawrence I., D'Andrea, Denise M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Special Populations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587782/ https://www.ncbi.nlm.nih.gov/pubmed/30452776 http://dx.doi.org/10.1002/jcph.1337

Ejemplares similares

CSL112 (Apolipoprotein A-I [Human]) Enhances Cholesterol Efflux Similarly in Healthy Individuals and Stable Atherosclerotic Disease Patients
por: Gille, Andreas, et al.
Publicado: (2018)

Pharmacometric analyses to characterize the effect of CSL112 on apolipoprotein A‐I and cholesterol efflux capacity in acute myocardial infarction patients
por: Zheng, Bo, et al.
Publicado: (2020)

Pharmacokinetics and Safety of CSL112 (Apolipoprotein A‐I [Human]) in Adults With Moderate Renal Impairment and Normal Renal Function
por: Tortorici, Michael A., et al.
Publicado: (2018)

Antiatherosclerotic Effects of CSL112 Mediated by Enhanced Cholesterol Efflux Capacity
por: Kingwell, Bronwyn A., et al.
Publicado: (2022)

Correction to: Antiatherosclerotic Effects of CSL112 Mediated by Enhanced Cholesterol Efflux Capacity
Publicado: (2023)

Effect of CSL112 (apolipoprotein A‐I [human]) on cholesterol efflux capacity in Japanese subjects: Findings from a phase I study and a cross‐study comparison
por: Zheng, Bo, et al.
Publicado: (2022)

Enhanced HDL Functionality in Small HDL Species Produced Upon Remodeling of HDL by Reconstituted HDL, CSL112: Effects on Cholesterol Efflux, Anti-Inflammatory and Antioxidative Activity
por: Didichenko, Svetlana A., et al.
Publicado: (2016)

Evaluation of potential antiplatelet effects of CSL112 (Apolipoprotein A-I [Human]) in patients with atherosclerosis: results from a phase 2a study
por: Gurbel, Paul A., et al.
Publicado: (2018)

Large-Scale Analysis of Determinants, Stability, and Heritability of High-Density Lipoprotein Cholesterol Efflux Capacity
por: Koekemoer, Andrea L., et al.
Publicado: (2017)

Clinical Pharmacokinetics and Pharmacodynamics of CSL112
por: Ortega-Paz, Luis, et al.
Publicado: (2023)

Cholesterol Mass Efflux Capacity, Incident Cardiovascular Disease, and Progression of Carotid Plaque: The Multi-Ethnic Study of Atherosclerosis
por: Shea, Steven, et al.
Publicado: (2019)

Biological basis and proposed mechanism of action of CSL112 (apolipoprotein A-I [human]) for prevention of major adverse cardiovascular events in patients with myocardial infarction
por: Korjian, Serge, et al.
Publicado: (2023)

Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I)
por: Michael Gibson, C., et al.
Publicado: (2016)

Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial
por: Tricoci, Pierluigi, et al.
Publicado: (2015)

Cholesterol efflux capacity assay using immobilized liposomes and apolipoprotein B-depleted serum
por: Sapa, Hima Rani
Publicado: (2019)

Guanosine effect on cholesterol efflux and apolipoprotein E expression in astrocytes
por: Ballerini, Patrizia, et al.
Publicado: (2006)

Cholesterol efflux capacity is associated with lipoprotein size and vascular health in mild to moderate psoriasis
por: Berg, Alexander R., et al.
Publicado: (2023)

Apolipoprotein M promotes cholesterol uptake and efflux from mouse macrophages
por: Yao, Shuang, et al.
Publicado: (2021)

Cholesterol Efflux Capacity of Apolipoprotein A-I Varies with the Extent of Differentiation and Foam Cell Formation of THP-1 Cells
por: Yano, Kouji, et al.
Publicado: (2016)

Usefulness of apolipoprotein B-depleted serum in cholesterol efflux capacity assays using immobilized liposome-bound gel beads
por: Horiuchi, Yuna, et al.
Publicado: (2019)

Uremia alters HDL composition and cholesterol efflux capacity
por: Holzer, Michael, et al.
Publicado: (2012)

Moderate‐ and High‐Intensity Exercise Improves Lipoprotein Profile and Cholesterol Efflux Capacity in Healthy Young Men
por: Stanton, Kelly M., et al.
Publicado: (2022)

Development and validation of novel automatable assay for cholesterol efflux capacity
por: Mutsuda, Yume, et al.
Publicado: (2023)

Relationship between HDL Cholesterol Efflux Capacity, Calcium Coronary Artery Content, and Antibodies against ApolipoproteinA-1 in Obese and Healthy Subjects
por: Vuilleumier, Nicolas, et al.
Publicado: (2019)

Caveolin-1-Mediated Apolipoprotein A-I Membrane Binding Sites Are Not Required for Cholesterol Efflux
por: Le Lay, Soazig, et al.
Publicado: (2011)

Stability and change in male fertility patterns by cognitive ability across 32 birth cohorts
por: Bratsberg, Bernt, et al.
Publicado: (2023)

Genetic Loci Governing Androgenic Capacity in Perennial Ryegrass (Lolium perenne L.)
por: Begheyn, Rachel F., et al.
Publicado: (2018)

The negative effect of ANGPTL8 on HDL-mediated cholesterol efflux capacity
por: Luo, Mengdie, et al.
Publicado: (2018)

Lower than average HDL cholesterol efflux capacity in Lithuanian population
por: Kutkiene, Sandra, et al.
Publicado: (2019)

HDL cholesterol efflux capacity and lipid profile in patients with systemic sclerosis
por: Ferraz-Amaro, Iván, et al.
Publicado: (2021)

Effect of Anacetrapib on Cholesterol Efflux Capacity: A Substudy of the DEFINE Trial
por: Metzinger, Mark P., et al.
Publicado: (2020)

Structural properties of apolipoprotein A-I mimetic peptides that promote ABCA1-dependent cholesterol efflux
por: Islam, Rafique M., et al.
Publicado: (2018)

Conformational flexibility of apolipoprotein A-I amino- and carboxy-termini is necessary for lipid binding but not cholesterol efflux
por: Bedi, Shimpi, et al.
Publicado: (2022)

Cholesterol Efflux Capacity and Its Association With Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis
por: Lee, Jane J., et al.
Publicado: (2021)

It’s Time to Reassess the High-Density Lipoprotein (HDL) Hypothesis: CSL112, a Novel Promising Reconstituted HDL Formulation
por: Marsche, Gunther
Publicado: (2015)

Fungal CSL transcription factors
por: Převorovský, Martin, et al.
Publicado: (2007)

Effect of Mild and Moderate Hepatic Impairment (Defined by Child–Pugh Classification and National Cancer Institute Organ Dysfunction Working Group Criteria) on Pexidartinib Pharmacokinetics
por: Zahir, Hamim, et al.
Publicado: (2022)

Targeted cholesterol efflux
por: Fang, Longhou, et al.
Publicado: (2013)

Extracellular lipid-free apolipoprotein E inhibits HCV replication and induces ABCG1-dependent cholesterol efflux
por: Crouchet, Emilie, et al.
Publicado: (2017)

Single‐Center Evaluation of the Pharmacokinetics and Safety of the Angiotensin II Receptor Antagonist Azilsartan Medoxomil in Mild to Moderate Hepatic Impairment
por: Dudkowski, Caroline, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_e2ct0l9bg04m3vt8o24eoga8gu